Despite profits and steady growth, investigative sites are under-investing in patient recruitment and staff recruitment.
Sites also face significant cash flow problems and declining grant sizes.
The appeal for the hospitals is that Intercern's involvement should increase the hospitals' number of studies and patient enrollment. Furthermore, Intercern will expand its network to include hospitals on the continent. This European expansion is planned for mid-2000. Recently, there has been a rapid growth of the number of type 2 diabetes drugs being introduced. CenterWatch has identified 39 of these drugs currently in the clinical pipeline.